Bromocriptine (Uzbek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bromocriptine" in Uzbek language version.

refsWebsite

Global rank Uzbek rank

22nih.gov

4^th place

7^th place

18doi.org

2^nd place

3^rd place

4web.archive.org

1^st place

2books.google.com

3^rd place

4^th place

1drugs.com

399^th place

440^th place

1diabetesjournals.org

low place

9,411^th place

1europa.eu

68^th place

50^th place

1aerzteblatt.de

3,043^rd place

low place

1uzh.ch

3,633^rd place

5,285^th place

1unc.edu

1,538^th place

4,717^th place

aerzteblatt.de

m.aerzteblatt.de

„EMA rät vom Abstillmittel Bromocriptin ab“ (2014-yil 25-avgust). 2015-yil 9-iyunda asl nusxadan arxivlangan. Qaraldi: 2014-yil 26-avgust. "EMA rät vom Abstillmittel Bromocriptin ab", article in Ärzteblatt

books.google.com

Analogue-based Drug Discovery (en). John Wiley & Sons, 2006 — 533-bet. ISBN 9783527607495.
Drug Discovery: A History (en). John Wiley & Sons, 2005 — 352-bet. ISBN 9780471899792.

diabetesjournals.org

care.diabetesjournals.org

„Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes“. Diabetes Care. 34-jild, № 4. April 2011. 789–94-bet. doi:10.2337/dc11-0064. PMC 3064029. PMID 21447659.

doi.org

„Diagnosis and Treatment of Pituitary Adenomas: A Review“. JAMA. 317-jild, № 5. February 2017. 516–524-bet. doi:10.1001/jama.2016.19699. PMID 28170483.
„Dopamine agonists for preventing ovarian hyperstimulation syndrome“. The Cochrane Database of Systematic Reviews. 14-Apr 2021-yil. doi:10.1002/14651858.CD008605.pub4. PMC 8092425. PMID 33851429.{{cite magazine}}: CS1 maint: date format ()
„Dopamine agonists for the treatment of cocaine dependence“. The Cochrane Database of Systematic Reviews. № 5. May 2015. CD003352-bet. doi:10.1002/14651858.CD003352.pub4. PMC 6999795. PMID 26014366. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations“. Endocrine Practice. 19-jild, № 1. 2013. 100–6-bet. doi:10.4158/EP12325.OR. PMID 23337160.
„Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis“. Hormone and Metabolic Research. 47-jild, № 11. October 2015. 805–12-bet. doi:10.1055/s-0035-1559684. PMID 26332757. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes“. Diabetes Care. 34-jild, № 4. April 2011. 789–94-bet. doi:10.2337/dc11-0064. PMC 3064029. PMID 21447659.
„The safety of bromocriptine in long-term use: a review of the literature“. Current Medical Research and Opinion. 10-jild, № 1. 1986. 25–51-bet. doi:10.1185/03007998609111089. PMID 3516579.
„Bromocriptine and psychosis: a literature review“. The Psychiatric Quarterly. 66-jild, № 1. 1995. 87–95-bet. doi:10.1007/BF02238717. PMID 7701022.
„Flagging Drugs That Inhibit the Bile Salt Export Pump“ (PDF). Molecular Pharmaceutics. 13-jild, № 1. January 2016. 163–71-bet. doi:10.1021/acs.molpharmaceut.5b00594. PMID 26642869. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„Dopamine agonist withdrawal syndrome: implications for patient care“. Drugs & Aging. 30-jild, № 8. August 2013. 587–92-bet. doi:10.1007/s40266-013-0090-z. PMID 23686524.
„The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells“. Biochemical Pharmacology. 79-jild, № 12. June 2010. 1827–36-bet. doi:10.1016/j.bcp.2010.01.029. PMID 20138024. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal“. European Journal of Pharmacology. 643-jild, № 1. September 2010. 48–57-bet. doi:10.1016/j.ejphar.2010.06.007. PMID 20599932.
„Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy“. J Pharmacol Toxicol Methods. 69-jild, № 2. 2014. 150–61-bet. doi:10.1016/j.vascn.2013.12.004. PMID 24361689.
Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). „Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes“. J Pharmacol Exp Ther. 303-jild, № 2. 791–804-bet. doi:10.1124/jpet.102.039867. PMID 12388666.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). „Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor“. J Pharmacol Exp Ther. 303-jild, № 2. 805–14-bet. doi:10.1124/jpet.102.039875. PMID 12388667.
Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ (November 2002). „Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes“. J Pharmacol Exp Ther. 303-jild, № 2. 815–22-bet. doi:10.1124/jpet.102.039883. PMID 12388668.
„Fungal Metabolites as Pharmaceuticals“. Australian Journal of Chemistry. 67-jild, № 6. 2014. 827-bet. doi:10.1071/CH13639.
„Bromocriptine: old drug, new formulation and new indication“. Diabetes, Obesity & Metabolism. 12-jild, № 12. December 2010. 1048–57-bet. doi:10.1111/j.1463-1326.2010.01304.x. PMID 20977575.

drugs.com

„Bromocriptine international brand names“. Drugs.com. 6-avgust 2017-yilda asl nusxadan arxivlangan. Qaraldi: 13-iyul 2017-yil.

europa.eu

ema.europa.eu

„European Medicines Agency - News and Events - CMDh endorses restricted use of bromocriptine for stopping breast milk production“. www.ema.europa.eu (2018-yil 17-sentyabr). 2014-yil 28-avgustda asl nusxadan arxivlangan.

nih.gov

pubmed.ncbi.nlm.nih.gov

„Diagnosis and Treatment of Pituitary Adenomas: A Review“. JAMA. 317-jild, № 5. February 2017. 516–524-bet. doi:10.1001/jama.2016.19699. PMID 28170483.
„Dopamine agonists for preventing ovarian hyperstimulation syndrome“. The Cochrane Database of Systematic Reviews. 14-Apr 2021-yil. doi:10.1002/14651858.CD008605.pub4. PMC 8092425. PMID 33851429.{{cite magazine}}: CS1 maint: date format ()
„Dopamine agonists for the treatment of cocaine dependence“. The Cochrane Database of Systematic Reviews. № 5. May 2015. CD003352-bet. doi:10.1002/14651858.CD003352.pub4. PMC 6999795. PMID 26014366. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations“. Endocrine Practice. 19-jild, № 1. 2013. 100–6-bet. doi:10.4158/EP12325.OR. PMID 23337160.
„Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis“. Hormone and Metabolic Research. 47-jild, № 11. October 2015. 805–12-bet. doi:10.1055/s-0035-1559684. PMID 26332757. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes“. Diabetes Care. 34-jild, № 4. April 2011. 789–94-bet. doi:10.2337/dc11-0064. PMC 3064029. PMID 21447659.
„The safety of bromocriptine in long-term use: a review of the literature“. Current Medical Research and Opinion. 10-jild, № 1. 1986. 25–51-bet. doi:10.1185/03007998609111089. PMID 3516579.
„Bromocriptine related atypical vascular accidents postpartum identified through medicolegal reviews“. Medicine and Law. 15-jild, № 1. 1996. 127–34-bet. PMID 8691994.
„Bromocriptine and psychosis: a literature review“. The Psychiatric Quarterly. 66-jild, № 1. 1995. 87–95-bet. doi:10.1007/BF02238717. PMID 7701022.
„Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease“. Clinical and Experimental Neurology. 27-jild. 1990. 79–82-bet. PMID 2129961.
„Flagging Drugs That Inhibit the Bile Salt Export Pump“ (PDF). Molecular Pharmaceutics. 13-jild, № 1. January 2016. 163–71-bet. doi:10.1021/acs.molpharmaceut.5b00594. PMID 26642869. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„Dopamine agonist withdrawal syndrome: implications for patient care“. Drugs & Aging. 30-jild, № 8. August 2013. 587–92-bet. doi:10.1007/s40266-013-0090-z. PMID 23686524.
„The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells“. Biochemical Pharmacology. 79-jild, № 12. June 2010. 1827–36-bet. doi:10.1016/j.bcp.2010.01.029. PMID 20138024. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal“. European Journal of Pharmacology. 643-jild, № 1. September 2010. 48–57-bet. doi:10.1016/j.ejphar.2010.06.007. PMID 20599932.
„Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy“. J Pharmacol Toxicol Methods. 69-jild, № 2. 2014. 150–61-bet. doi:10.1016/j.vascn.2013.12.004. PMID 24361689.
Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). „Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes“. J Pharmacol Exp Ther. 303-jild, № 2. 791–804-bet. doi:10.1124/jpet.102.039867. PMID 12388666.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). „Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor“. J Pharmacol Exp Ther. 303-jild, № 2. 805–14-bet. doi:10.1124/jpet.102.039875. PMID 12388667.
Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ (November 2002). „Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes“. J Pharmacol Exp Ther. 303-jild, № 2. 815–22-bet. doi:10.1124/jpet.102.039883. PMID 12388668.
„Bromocriptine: old drug, new formulation and new indication“. Diabetes, Obesity & Metabolism. 12-jild, № 12. December 2010. 1048–57-bet. doi:10.1111/j.1463-1326.2010.01304.x. PMID 20977575.

ncbi.nlm.nih.gov

„Dopamine agonists for preventing ovarian hyperstimulation syndrome“. The Cochrane Database of Systematic Reviews. 14-Apr 2021-yil. doi:10.1002/14651858.CD008605.pub4. PMC 8092425. PMID 33851429.{{cite magazine}}: CS1 maint: date format ()
„Dopamine agonists for the treatment of cocaine dependence“. The Cochrane Database of Systematic Reviews. № 5. May 2015. CD003352-bet. doi:10.1002/14651858.CD003352.pub4. PMC 6999795. PMID 26014366. {{cite magazine}}: Invalid |display-authors=6 (yordam)
„Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes“. Diabetes Care. 34-jild, № 4. April 2011. 789–94-bet. doi:10.2337/dc11-0064. PMC 3064029. PMID 21447659.

unc.edu

pdsp.med.unc.edu

National Institute of Mental Health. PDSP Ki Database (Internet). ChapelHill (NC): University of North Carolina. Available from: „Archived copy“. 2021-yil 12-aprelda asl nusxadan arxivlangan. Qaraldi: 2021-yil 12-aprel.

uzh.ch

zora.uzh.ch

„Flagging Drugs That Inhibit the Bile Salt Export Pump“ (PDF). Molecular Pharmaceutics. 13-jild, № 1. January 2016. 163–71-bet. doi:10.1021/acs.molpharmaceut.5b00594. PMID 26642869. {{cite magazine}}: Invalid |display-authors=6 (yordam)

web.archive.org

„Bromocriptine international brand names“. Drugs.com. 6-avgust 2017-yilda asl nusxadan arxivlangan. Qaraldi: 13-iyul 2017-yil.
„European Medicines Agency - News and Events - CMDh endorses restricted use of bromocriptine for stopping breast milk production“. www.ema.europa.eu (2018-yil 17-sentyabr). 2014-yil 28-avgustda asl nusxadan arxivlangan.
„EMA rät vom Abstillmittel Bromocriptin ab“ (2014-yil 25-avgust). 2015-yil 9-iyunda asl nusxadan arxivlangan. Qaraldi: 2014-yil 26-avgust. "EMA rät vom Abstillmittel Bromocriptin ab", article in Ärzteblatt
National Institute of Mental Health. PDSP Ki Database (Internet). ChapelHill (NC): University of North Carolina. Available from: „Archived copy“. 2021-yil 12-aprelda asl nusxadan arxivlangan. Qaraldi: 2021-yil 12-aprel.